RELAPSED NEUROBLASTOMA
Clinical trials for RELAPSED NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for RELAPSED NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cell army targets childhood cancers in new trial
Disease control Recruiting nowThis early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has not responded to standard therapy or has returned. The approach combines specially grown immune cells (gamma delta T cells) from a healthy donor with several chemotherapy drugs and a…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New CAR t therapy targets tough childhood cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment for children with neuroblastoma that has come back or is hard to treat. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer. The main goal is to find a safe dose and understand side effects. Up …
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Engineered immune cells take aim at childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment called hALK.CAR T cells for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and atta…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Engineered immune cells take aim at childhood cancer
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has returned or not responded to standard treatments. The goal is to find a safe do…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
New hope for kids with Tough-to-Treat cancer: BEACON2 trial launches
Disease control Recruiting nowThis study tests new combinations of drugs for children and young adults whose neuroblastoma has come back or not responded to standard treatment. About 160 participants will receive one of three treatment regimens to see which works best and is safest. The goal is to improve sur…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or retinoblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and at…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
Disease control Recruiting nowThis study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Theodore Laetsch • Aim: Disease control
Last updated May 11, 2026 20:52 UTC